Who owns Estomazil?
Estomazil is owned by Hypera (Brazil, B3: HYPE3).[1]
This ownership is reported in official statements but has not yet been matched to a regulatory filing.
Key facts
- Current owner
- Hypera Pharma reported
- Owned since
- Not recorded
- Previous owner
- None recorded
- Owner HQ
- 🇧🇷 Brazil, São Paulo
- Origin
- 🇧🇷 Brazil
- Category
- Consumer health › Over-the-counter medicine › Digestive health
- Parent ticker
- B3: HYPE3
- Last verified
- · 1 sources
About Estomazil
Estomazil is Hypera Pharma's antacid brand for heartburn and indigestion. It is sold as an effervescent sodium bicarbonate powder in 5-gram sachets flavoured with pineapple, orange or guaraná or unflavoured, as chewable tablets, and as Leite de Magnésia Estomazil, a milk of magnesia that also works as a mild laxative.
Ownership timeline of Estomazil
Where Estomazil sits in Hypera
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Hypera ownership tree →
Other brands owned by Hypera in consumer health
Latest news about Estomazil
No tagged news items yet. Deals, regulatory actions and recalls are added from SEC filings, regulators and trade press; only titles and links are stored.
Headlines link to the original publisher. Brandtree does not reproduce article text.
Frequently asked questions
Who is the parent company of Estomazil?
The parent company of Estomazil is Hypera, a publicly listed company headquartered in Brazil.
Is Estomazil Brazilian?
Yes. Estomazil originated in Brazil and its owner, Hypera, is also headquartered in Brazil.
Is Estomazil still owned by Hypera?
Yes. As of 16 September 2026, Estomazil is still owned by Hypera. The ownership record was last checked against primary sources on that date.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Hypera Pharma — Corporate Profile (investor relations, updated 18 June 2026) — Hypera Pharma, Official document, published 18 June 2026; retrieved 16 September 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.